Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-798-3 | CAS number: 126-71-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Neurotoxicity
Administrative data
Description of key information
After two doses of 5000 mg/kg bw of Triisobutyl phosphate in hens by
gavage, no effects were observed.
Furthermore, a single oral 5000 mg/kg bw dose Triisobutyl phosphate did
not significantly inhibit hen brain neurotoxic esterase 24 hours after
administration. The results suggest that Triisobutyl phosphate does not
produce delayed neurotoxicity in hens.
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Link to relevant study records
- Endpoint:
- neurotoxicity: acute oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 06.02.1986 - 20.03.1986
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 418 (Delayed Neurotoxicity of Organophosphorus Substances Following Acute Exposure)
- GLP compliance:
- not specified
- Limit test:
- no
- Specific details on test material used for the study:
- - Name of test material: Etingal
- Physical state: liquid
- Analytical purity: 99.7%
- Purity test date: 1984-05-28
- Lot/batch No.: 84/175
- Stability under test conditions: unlimited
- Storage condition of test material: Room temperatur - Species:
- hen
- Strain:
- other: Hybridstamm
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Frima Leib. landwirtschaftlicher Betrieb, Hassloch/Pfalz, BRD
- Age at study initiation: 12-14 Months
- Weight at study initiation: not specified
- Fasting period before study: not specified
- Housing: as a group in an aviary
- Diet: from 28.10.85; Legehennen-Alleinfutter 9B Pres (Frima Raiffeisen). From 21.12.85; Hübler Ln/G-Futter (Firma Ssniff Spezialdiäten GmbH). From 13.02.86; LA-Eierblitz, Alleinfutter für Legehennen (Firma Ssniff Spezialdiäten GmbH).
- Water (ad libitum): Tapwater
- Acclimation period: 3 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): ca. 20
- Humidity (%): 50-60
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): not specified
IN-LIFE DATES: no data - Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Remarks:
- DAB8
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- preperation on the day of exposure
- concentrations: 0, 5, 10, 20, 50%
VEHICLE
- Justification for use and choice of vehicle: not specified
- Amount: 10 mL/kg bw
- Purity: not specified - Analytical verification of doses or concentrations:
- not specified
- Frequency of treatment:
- 500 and 1000 mg/kg bw: 1 treatment
2000 and 5000 mg/kg bw: 2 treatments (2nd after 21 days) - Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- Remarks:
- one treatment
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- one treatment
- Dose / conc.:
- 2 000 mg/kg bw/day (actual dose received)
- Remarks:
- two treatments
- Dose / conc.:
- 5 000 mg/kg bw/day (actual dose received)
- Remarks:
- two treatments
- No. of animals per sex per dose:
- Contol group 1 and 2: 5 females per group
Test group 3: 4 females
Test group 4, 5 and 6: 5 females per group
Positive contol group 7, 8 and 9: 5 females per group - Control animals:
- yes, concurrent vehicle
- other: Tri-ortho-cresylphosphat solved in olive oil
- Details on study design:
- - Dose selection rationale: according to OECD guideline maximal 5000 mg/kg bw is required
- Rationale for animal assignment: random
- Rationale for selecting satellite groups: not specified
- Post-exposure recovery period in satellite groups: no data - Observations and clinical examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- mortality and symptomatology: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: on day 42
BODY WEIGHT: Yes
- Time schedule for examinations: day 1 and day 42. On day 21 for the test groups with doses 2000 and 5000 mg/kg bw.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, the first 6 days
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Not applicable.
WATER CONSUMPTION AND COMPOUND INTAKE: No
OPHTHALMOSCOPIC EXAMINATION: No data
OTHER: NEUROTOXIC SURVEY FINDINGS
- Time schedule for examinations: on day 1, 5, 20 and 42 - Specific biochemical examinations:
- NEUROPATHY TARGET ESTERASE (NTE) ACTIVITY: No data
CHOLINESTERASE ACTIVITY: No data - Neurobehavioural examinations performed and frequency:
- The animals were individually placed on a 40 cm high box and forced to jump, on day 1, 5, 20 and 42.
- Sacrifice and (histo)pathology:
- - Time point of sacrifice: day 42
- Number of animals sacrificed: all
- Parameters measured: not specified
- Brain weight: no data
- Length and width of brain: no data
- Procedures for perfusion: not specified
- Number of animals perfused: no data
- Tissues evaluated: Parameters checked in table were examined: no
- Type of staining: no data
- Methodology of preparation of sections: no data
- Thickness: no data
- Embedding media: no data
- Number of sections: no data
- Number of animals evaulated from each sex and treatment group: all animals - Positive control:
- CAGE SIDE OBSERVATIONS: Yes
- mortality and symptomatology: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: on day 42
BODY WEIGHT: Yes
- Time schedule for examinations: day 1 and day 42.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, the first 6 days
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: not applicable
WATER CONSUMPTION AND COMPOUND INTAKE: No
OPHTHALMOSCOPIC EXAMINATION: No data
OTHER: NEUROTOXIC SURVEY FINDINGS
- Time schedule for examinations: on day 1, 5, 20 and 42 - Statistics:
- No data
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Behaviour (functional findings):
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not specified
- Details on results:
- In the positive control animals, treatment-related deaths (5 of 15), serious of severe neurotoxic symptoms (7 of 15) and weight loss occurred, while in the triisobutyl phosphate-treated hens there were no effects that could be attributed to treatment, even after the administration of two doses of 5000 mg/kg bw.
- Dose descriptor:
- NOAEL
- Effect level:
- 5 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Critical effects observed:
- not specified
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 5 000 mg/kg bw/day
- Species:
- hen
Effect on neurotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A study of the possible neurotoxic effect of Triisobutyl phosphate (99,7% pure) was carried out based on OECD 418 in groups of 5 adult domestic hens (aged ca. 12 to 14 months) (BASF, 1987). Two groups were given single doses of 500 and 1000 mg/kg bw, respectively, (dissolved in olive oil) by gavage and were then observed for 42 days. Further groups were given single doses of 2000 and 5000 mg/kg bw, respectively, and were then given the same dose again 21 days later with a total observation period of 42 days. As a positive control 3 groups of 5 hens were given a single dose of 500 mg tri-o cresyl phosphate/kg bw by gavage (also in olive oil) and were also observed for 42 days. In the positive control animals, treatment-related deaths (5 of 15), serious of severe neurotoxic symptoms (7 of 15) and weight loss occurred, while in thetriisobutyl phosphate-treated hens there were no effects that could be attributed to treatment, even after the administration of two doses of 5000 mg/kg bw.
The effect of a single oral dose of Triisobutyl phosphate(TiBP) on white hen brain neurotoxic esterase (NTE) and acetylcholinesterase (AChE) and plasma butyrylcholinesterase (BuChE) was determined 24 hours after receiving a single oral dose (Monsanto, 1990). A 5000 mg/kg bw dose was used since it exceeded the oral LD50 dose in unprotected hens again the acute cholinergic effects of TiBP. This dose caused statistically significant inhibition of plasma BuChE activity (98.1% inhibition), yet neither brain NTE nor AChE was significantly inhibited by this treatment. The inhibition of 9.45 of brain NTE suggests that TiBP does not produce delayed neurotoxicity in hens since an inhibition of approximately 75% of brain NTE 24 hours after dosing is required for an organophosphorus compound to have the potential to produce delayed neurotoxicity. This conclusion is supported by the findings that a delayed neurotoxic dose of tri-o-cresyl phosphate (TOCP) significantly inhibited brain NTE (86.2% inhibition). This TOCP dose also significantly inhibited plasma BuChE (89.2% inhibition) and brain AChE (20.7% inhibition), neither of which is directly involved in the development of delayed neurotoxicity.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. Based on the results of the oral delayed neurotoxicity study, the substance does not need to be classified for neurotoxicity under Regulation (EC) No. 1272/2008, as amended for the tenth time in Regulation (EC) No. 2017/776.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.